Core Viewpoint - The report outlines a significant equity change involving Wanbangde Pharmaceutical Holdings Group Co., Ltd., where the information disclosure obligor, Wenling Wanlong Pharmaceutical Technology Partnership (Limited Partnership), is set to acquire 60 million shares, representing 9.8089% of the company's total equity through a private transfer agreement [1][4]. Group 1: Equity Change Details - The equity change is a result of an agreement signed on July 11, 2025, between Wenlong Pharmaceutical and several transferors, including Zhao Shouming and Zhuang Hui, to transfer a total of 60 million shares [1][5]. - The transfer price is set at 6.88 RMB per share, totaling 412.8 million RMB for the entire transaction [5][6]. - The transferors include Zhao Shouming (12,410,000 shares), Zhuang Hui (7,050,000 shares), and others, with the largest transferor being Wanbangde Group (17,039,326 shares) [5][6]. Group 2: Compliance and Future Plans - The equity change must comply with the regulations of the Shenzhen Stock Exchange and requires the completion of share transfer registration with the China Securities Depository and Clearing Corporation [2][6]. - The information disclosure obligor commits not to reduce its holdings of the acquired shares within 12 months following the completion of the transfer [3][4]. - There are no plans for the information disclosure obligor to increase its stake in the company within the next 12 months [3][4].

Summary of Key Points Core Viewpoint - The announcement details the agreement for the transfer of 60,000,000 shares of Wanbangde Pharmaceutical Holdings Group Co., Ltd., representing 9.8089% of the total share capital, from its controlling shareholders to Wanzhong Medicine, with a transfer price of 6.88 RMB per share, totaling approximately 412.8 million RMB [1][2][5]. Group 1: Agreement Overview - The transfer involves Wanbangde Group, its actual controllers Zhao Shouming and Zhuang Hui, and their concerted actions, transferring shares to Wanzhong Medicine [1][2]. - The total transfer price is set at 6.88 RMB per share, amounting to 412.8 million RMB for the entire transaction [2][5]. - The transaction is subject to compliance review by the Shenzhen Stock Exchange before the transfer can be completed [3][6]. Group 2: Shareholding Changes - Following the transfer, the shareholding structure will change, with Wanbangde Group's stake decreasing from 31.6217% to 28.8361%, and Zhao Shouming's from 8.1213% to 6.0925% [2][3]. - Wanzhong Medicine will acquire 60,000,000 shares, establishing a new ownership stake of 9.8089% in the company [2][5]. Group 3: Impact on Company Control - The transfer does not trigger a change in control, as the combined shareholding of the controlling shareholders will remain at 40.6656% post-transaction [7][8]. - The governance structure and ongoing operations of the company are not expected to be significantly affected by this share transfer [7][8]. Group 4: Compliance and Restrictions - Wanzhong Medicine has committed not to sell the acquired shares for twelve months following the completion of the transfer [2][7]. - The transaction adheres to relevant regulations, including the Management Measures for the Acquisition of Listed Companies and the Shenzhen Stock Exchange's guidelines [3][8].

证券代码：002082 证券简称：万邦德 公告编号：2025-042 万邦德医药控股集团股份有限公司 关于控股股东、实际控制人及一致行动人 拟协议转让公司部分股份暨权益变动的提示性公告 公司控股股东、实际控制人及其一致行动人和受让方保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、万邦德医药控股集团股份有限公司（以下简称"公司"）控股股东万邦 德集团有限公司（以下简称"万邦德集团"）、实际控制人赵守明先生、庄惠女 士、一致行动人温岭惠邦投资咨询有限公司（以下简称"温岭惠邦"）、温岭富 邦投资咨询有限公司（以下简称"温岭富邦"）拟通过协议转让方式，向温岭市 万龙医药科技合伙企业（有限合伙）(以下简称"万龙医药"）转让其持有的公 司股票合计 60,000,000 股，占公司总股本的 9.8089%。（以下简称"本次交易"） 2、本次交易不涉及要约收购，不涉及关联交易。 3、本次交易不会导致公司控制权发生变化，不会对公司治理结构及持续经 营产生重大影响。 4、本次交 ...

万邦德医药控股集团股份有限公司 简式权益变动报告书 上市公司名称：万邦德医药控股集团股份有限公司 上市地点：深圳证券交易所 股票简称：万邦德 股票代码：002082.SZ 信息披露义务人：温岭市万龙医药科技合伙企业（有限合伙） 主要经营场所：浙江省台州市温岭市城东街道阳光大道157号科创大厦13楼 1309室 股份变动性质：股份增加（协议转让） 签署日期：2025年7月11日 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在万邦德医药控股集团股份有限公司拥有 权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述 信息披露义务人没有通过任何其他方式增加或减少其在万邦德中拥有权益的股 份。 四、 ...

万邦德医药控股集团股份有限公司 简式权益变动报告书 上市公司名称：万邦德医药控股集团股份有限公司 信息披露义务人一：万邦德集团有限公司 住所及通讯地址：浙江省台州市温岭市城东街道楼山村百丈路西侧 信息披露义务人二：赵守明 住所及通讯地址：浙江省温岭市**** 信息披露义务人三：庄惠 住所及通讯地址：浙江省温岭市**** 信息披露义务人四：温岭惠邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 信息披露义务人五：温岭富邦投资咨询有限公司 住所及通讯地址：温岭市城东街道楼山村百丈路西侧 股份变动性质：股份减少（协议转让） 签署日期：二〇二五年七月十一日 上市地点：深圳证券交易所 股票简称：万邦德 股票代码：002082.SZ 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15号——权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和 ...

万邦德：控股股东等拟协议转让公司9.8089%股份 智通财经7月11日电，万邦德(002082.SZ)公告称，公司控股股东万邦德集团、实际控制人赵守明、庄 惠、一致行动人温岭惠邦、温岭富邦拟通过协议转让方式，向温岭市万龙医药科技合伙企业转让其持有 的公司股票合计6000万股，占公司总股本的9.8089%。转让价格为6.88元/股，股份转让总价款合计为 4.128亿元。 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-041 万邦德医药控股集团股份有限公司 股东名 称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质 押股份数量 (股) 占其所 持股份 比例（%） 占公司总 股本比例 （%） 质押起 始日 质押解 除日 质权人 赵守明 是 150,000 0.30 0.02 2023 年 7 月 7 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 赵守明 是 10,000,000 20.13 1.63 2023 年 9 月 11 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 庄惠 是 9,850,000 34.89 1.61 2023 年 7 月 7 日 2025 年 7 月 7 日 浙股（杭州） 企业管理有限 公司 一、股东股份解除质押基本情况 三、股东股份累计质押情况 | | | | | | | | 已质押 | | 未质押 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | ...

一、 药物基本情况 药品名称：WP107 口服溶液 受理号：CXHL2500409 适应症：重症肌无力 申请事项：临床试验申请 申请人：万邦德制药集团有限公司 审批结论：同意本品开展"用于重症肌无力的治疗"适应症的临床试验。 证券代码：002082 证券简称：万邦德 公告编号：2025-040 万邦德医药控股集团股份有限公司 关于子公司药品获得《药物临床试验批准通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 核准签发的《药物临床试验批准通知书》，公司自主研发的 WP107 口服溶液用于 治疗"重症肌无力"的临床试验申请获得批准。现将相关情况公告如下： 本次药物临床试验获得批准，进一步加快公司在研产品的进度，短期内对公 司经营业绩不会产生重大影响，公司将按照相关规定和要求继续开展临床试验。 药品研发具有高投入、高风险、长周期等特点，临床试验进度及结果、未来 产品市场竞争形势均存在不确定性，会受到不可预测因素的 ...

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：002082 证券简称：万邦德 公告编号：2025-039 万邦德医药控股集团股份有限公司 关于控股股东及实际控制人股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）于近日收到控股股 东万邦德集团有限公司（以下简称"万邦德集团"）及实际控制人赵守明先生的 通知，获悉其所持有公司的部分股份办理了解除质押及再质押手续，具体事项如 下： | 股东名 | 是否为控股 股东或第一 | 本次解除质 | 占其所 | 占公司总 | 质押起 | 质押解 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 大股东及其 | 押股份数量 | 持股份 | 股本比例 | 始日 | 除日 | 质权人 | | | 一致行动人 | (股) | 比例（%） | （%） | | | | | 万邦德 | 是 | 106,460,000 | 55.04 | 17.40 | 2022 年 5 | 2025 年 6 | | | 集团 | | | | | ...